SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-028944
Filing Date
2020-06-11
Accepted
2020-06-11 09:26:38
Documents
14
Period of Report
2020-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K_BXLS_FUNDING_AGREEMENT reta-8k_20200610.htm   iXBRL 8-K 49018
2 EX-99.1_PR reta-ex991_6.htm EX-99.1 21424
3 GRAPHIC gntsoejvegtf000001.jpg GRAPHIC 23519
  Complete submission text file 0001564590-20-028944.txt   239283

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA reta-20200610.xsd EX-101.SCH 5772
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE reta-20200610_lab.xml EX-101.LAB 18734
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE reta-20200610_pre.xml EX-101.PRE 11172
7 EXTRACTED XBRL INSTANCE DOCUMENT reta-8k_20200610_htm.xml XML 3428
Mailing Address 5320 LEGACY DRIVE PLANO TX 75024
Business Address 5320 LEGACY DRIVE PLANO TX 75024 972-865-2219
REATA PHARMACEUTICALS INC (Filer) CIK: 0001358762 (see all company filings)

IRS No.: 113651945 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37785 | Film No.: 20956346
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences